Table 3.

PFAS serum concentrations ($\text{ng}/\mathrm{mL}$) among subcohort participants ($n=999$; 499 women and 500 men) and participants of the LifeLink Cohort with incident cancers.^a,b

Type of PFAS	Group	Both sexes			Women			Men
		P25	Median	P75	P25	Median	P75	P25	Median	P75
PFHpA	Subcohort	0.06	0.10	0.20	0.06	0.10	0.18	0.07	0.11	0.22
PFHpA	Bladder cancer cases	0.06	0.10	0.20	0.07	0.09	0.16	0.06	0.10	0.20
PFHpA	Breast cancer cases	NAc	NAc	NAc	0.06	0.10	0.19	NAc	NAc	NAc
PFHpA	Kidney cancer cases	0.07	0.11	0.19	0.07	0.10	0.16	0.07	0.11	0.21
PFHpA	Pancreas cancer cases	0.06	0.10	0.19	0.06	0.10	0.18	0.07	0.10	0.19
PFHpA	Prostate cancer cases	NAc	NAc	NAc	NAc	NAc	NAc	0.06	0.10	0.18
PFHpA	Hematologic malignancy cases	0.07	0.11	0.20	0.07	0.10	0.18	0.06	0.11	0.21
PFHxS	Subcohort	2.00	3.10	5.10	1.80	2.80	5.00	2.10	3.30	5.30
PFHxS	Bladder cancer cases	2.10	3.00	4.90	1.60	2.65	3.70	2.20	3.20	5.00
PFHxS	Breast cancer cases	NAc	NAc	NAc	1.70	2.80	5.20	NAc	NAc	NAc
PFHxS	Kidney cancer cases	2.10	3.30	4.90	2.20	3.05	4.90	2.05	3.35	4.65
PFHxS	Pancreas cancer cases	1.80	2.95	4.85	1.50	2.70	5.20	1.90	3.20	4.80
PFHxS	Prostate cancer cases	NAc	NAc	NAc	NAc	NAc	NAc	2.20	3.30	5.10
PFHxS	Hematologic malignancy cases	2.00	3.00	5.20	1.80	2.80	4.90	2.20	3.30	5.30
PFNA	Subcohort	0.49	0.67	0.98	0.49	0.67	0.96	0.49	0.67	0.99
PFNA	Bladder cancer cases	0.47	0.68	1.00	0.43	0.62	1.00	0.47	0.69	1.00
PFNA	Breast cancer cases	NAc	NAc	NAc	0.46	0.67	1.00	NAc	NAc	NAc
PFNA	Kidney cancer cases	0.51	0.68	1.00	0.51	0.66	0.98	0.52	0.72	1.00
PFNA	Pancreas cancer cases	0.45	0.63	1.00	0.43	0.62	0.97	0.47	0.63	1.00
PFNA	Prostate cancer cases	NAc	NAc	NAc	NAc	NAc	NAc	0.49	0.70	1.00
PFNA	Hematologic malignancy cases	0.45	0.65	1.00	0.45	0.63	0.99	0.45	0.68	1.00
PFOA	Subcohort	3.90	5.20	6.90	3.70	5.00	6.90	4.00	5.20	6.95
PFOA	Bladder cancer cases	3.80	5.10	6.70	3.60	4.30	6.60	3.90	5.20	6.80
PFOA	Breast cancer cases	NAc	NAc	NAc	3.70	5.00	6.90	NAc	NAc	NAc
PFOA	Kidney cancer cases	3.90	5.20	7.30	3.80	5.35	7.60	3.90	5.05	7.20
PFOA	Pancreas cancer cases	3.85	5.10	6.30	3.80	5.00	7.00	3.90	5.10	6.20
PFOA	Prostate cancer cases	NAc	NAc	NAc	NAc	NAc	NAc	4.00	5.30	6.90
PFOA	Hematologic malignancy cases	3.80	5.00	6.70	3.70	4.90	6.55	3.80	5.10	6.80
PFOS	Subcohort	13.00	18.00	25.00	13.00	18.00	25.00	13.50	18.00	25.50
PFOS	Bladder cancer cases	13.00	18.00	25.00	11.00	16.00	22.00	13.00	19.00	25.00
PFOS	Breast cancer cases	NAc	NAc	NAc	12.00	17.00	24.00	NAc	NAc	NAc
PFOS	Kidney cancer cases	13.00	18.00	26.00	11.00	19.50	27.00	14.00	18.00	24.00
PFOS	Pancreas cancer cases	12.00	18.00	25.00	11.00	18.00	25.00	12.00	19.00	25.00
PFOS	Prostate cancer cases	NAc	NAc	NAc	NAc	NAc	NAc	14.00	19.00	26.00
PFOS	Hematologic malignancy cases	12.00	17.00	24.00	12.00	16.00	23.00	13.00	18.00	25.00

Note: NA, not applicable; P25, 25th percentile; P75, 75th percentile; PFAS, per- and polyfluoroalkyl substances; PFHpA, perfluoroheptanoic acid; PFHxS, perfluorohexane sulfonic acid; PFNA, perfluorononanoic acid; PFOA, perfluorooctanoic acid; PFOS, perfluorooctane sulfonate.

^aValues below the limit of detection were imputed as the limit of detection divided by the square root of 2.

^bThe total number of cases of each type of cancer were as follows: bladder cancer, 401; breast cancer, 786; kidney cancer, 158; pancreas cancer, 172; prostate cancer, 1,610; hematologic malignancies, 635.

^cBreast cancer was considered for females only, and prostate cancer was considered for males only.